Literature DB >> 15825064

Increased risk of rectal cancer after prostate radiation: a population-based study.

Nancy N Baxter1, Joel E Tepper, Sara B Durham, David A Rothenberger, Beth A Virnig.   

Abstract

BACKGROUND & AIMS: Radiation therapy for prostate cancer has been associated with an increased rate of pelvic malignancies, particularly bladder cancer. The association between radiation therapy and colorectal cancer has not been established.
METHODS: We conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) registry data from 1973 through 1994. We focused on men with prostate cancer, but with no previous history of colorectal cancer, treated with either surgery or radiation who survived at least 5 years. We evaluated the effect of radiation on development of cancer for 3 sites: definitely irradiated sites (rectum), potentially irradiated sites (rectosigmoid, sigmoid, and cecum), and nonirradiated sites (the rest of the colon). Using a proportional hazards model, we evaluated the effect of radiation on development of colorectal cancer over time.
RESULTS: A total of 30,552 men received radiation, and 55,263 underwent surgery only. Colorectal cancers developed in 1437 patients: 267 in irradiated sites, 686 in potentially irradiated sites, and 484 in nonirradiated sites. Radiation was independently associated with development of cancer over time in irradiated sites but not in the remainder of the colon. The adjusted hazards ratio for development of rectal cancer was 1.7 for the radiation group, compared with the surgery-only group (95% CI: 1.4-2.2).
CONCLUSIONS: We noted a significant increase in development of rectal cancer after radiation for prostate cancer. Radiation had no effect on development of cancer in the remainder of the colon, indicating that the effect is specific to directly irradiated tissue.

Entities:  

Mesh:

Year:  2005        PMID: 15825064     DOI: 10.1053/j.gastro.2004.12.038

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  52 in total

1.  Estimate of the uncertainties in the relative risk of secondary malignant neoplasms following proton therapy and intensity-modulated photon therapy.

Authors:  Jonas D Fontenot; Charles Bloch; David Followill; Uwe Titt; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  Second malignancies in high‑dose areas of previous tumor radiotherapy.

Authors:  Birgitta Welte; Peter Suhr; Dirk Bottke; Detlef Bartkowiak; Wolfgang Dörr; Klaus Rüdiger Trott; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

3.  Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.

Authors:  Alexei Trofimov; Paul L Nguyen; John J Coen; Karen P Doppke; Robert J Schneider; Judith A Adams; Thomas R Bortfeld; Anthony L Zietman; Thomas F Delaney; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-21       Impact factor: 7.038

Review 4.  [Uro-oncology--update 2009].

Authors:  T Otto
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

5.  Avoid Downplaying Side Effects.

Authors:  Johannes Jongen; Volker Kahlke; Sven Petersen
Journal:  Dtsch Arztebl Int       Date:  2016-10-07       Impact factor: 5.594

6.  A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models.

Authors:  Bryan Bednarz; Basit Athar; X George Xu
Journal:  Med Phys       Date:  2010-05       Impact factor: 4.071

7.  Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study.

Authors:  Elizabeth J Davis; Jennifer L Beebe-Dimmer; Cecilia L Yee; Kathleen A Cooney
Journal:  Cancer       Date:  2014-05-19       Impact factor: 6.860

8.  Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer.

Authors:  Laura A Rechner; Rebecca M Howell; Rui Zhang; Carol Etzel; Andrew K Lee; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2012-10-10       Impact factor: 3.609

9.  The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer.

Authors:  R Diaz; P A Nguewa; J A Diaz-Gonzalez; E Hamel; O Gonzalez-Moreno; R Catena; D Serrano; M Redrado; D Sherris; A Calvo
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

10.  Prostate cancer as a first and second cancer: effect of family history.

Authors:  H Zhang; J L Bermejo; J Sundquist; K Hemminki
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.